Drug updated on 11/1/2024
| Dosage Form | Powder (inhalation; 400 mcg) |
| Drug Class | Anticholinergics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Aclidinium bromide/Formoterol (AB/FF) demonstrated the highest effectiveness in improving FEV1, with a SUCRA (surface under cumulative rankings) score of 97.7%, surpassing Umeclidinium/vilanterol (UMEC/VI) at 93.5%, Glycopyrrolate Formoterol Fumarate (GFF) at 84.7%, and Dupilumab at 66.9%, which ranked first among monoclonal antibodies (mAbs).
- The systematic review does not provide specific details regarding differences in effectiveness among various population types or subgroups.
- No significant safety concerns or adverse effects specific to Aclidinium bromide or its combination with Formoterol are mentioned in the study, although mAbs are indicated to have a good safety profile compared to placebo.
- Specific safety outcomes for Aclidinium bromide compared to other conventional agents were not detailed in the study.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tudorza Pressair (aclidinium bromide) Prescribing Information. | 2022 | Covis Pharma, Berkeley Heights, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease | 2024 | Frontiers in Medicine |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. | Global Initiative for Chronic Obstructive Lung Disease | |
| Global strategy for prevention, diagnosis and management of COPD. | Global Initiative for Chronic Obstructive Lung Disease |